180 related articles for article (PubMed ID: 30062986)
41. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
[TBL] [Abstract][Full Text] [Related]
42. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
[TBL] [Abstract][Full Text] [Related]
43. No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds.
Coulibaly YI; Sangare M; Dolo H; Soumaoro L; Coulibaly SY; Dicko I; Diabaté AF; Diarra L; Coulibaly ME; Doumbia SS; Diallo AA; Dembele M; Koudou BG; Bockarie MJ; Kelly-Hope LA; Klion AD; Nutman TB
Parasitol Res; 2022 Nov; 121(11):3243-3248. PubMed ID: 36066741
[TBL] [Abstract][Full Text] [Related]
44. Assessment of treatment impact on lymphatic filariasis in 13 districts of Benin: progress toward elimination in nine districts despite persistence of transmission in some areas.
Boko-Collins PM; Ogouyemi-Hounto A; Adjinacou-Badou EG; Gbaguidi-Saizonou L; Dossa NI; Dare A; Ibikounle M; Zoerhoff KL; Cohn DA; Batcho W
Parasit Vectors; 2019 May; 12(1):276. PubMed ID: 31146779
[TBL] [Abstract][Full Text] [Related]
45. Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria.
Anagbogu IN; Saka YA; Surakat OA; Okoronkwo C; Davies E; Oyale P; Ekpo UF; Amazigo UV; Barbre K; Igbe M; Nyior A; Jacob SM; Gideon Nteun U; Abubakar Umar Z
Parasit Vectors; 2022 Jun; 15(1):201. PubMed ID: 35698164
[TBL] [Abstract][Full Text] [Related]
46. Status of Onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision.
Evans DS; Alphonsus K; Umaru J; Eigege A; Miri E; Mafuyai H; Gonzales-Peralta C; Adamani W; Pede E; Umbugadu C; Saka Y; Okoeguale B; Richards FO
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3113. PubMed ID: 25233351
[TBL] [Abstract][Full Text] [Related]
47. Achievements and challenges of lymphatic filariasis elimination in Sierra Leone.
Bah YM; Paye J; Bah MS; Conteh A; Redwood-Sawyerr V; Sonnie M; Veinoglou A; Koroma JB; Hodges MH; Zhang Y
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008877. PubMed ID: 33370270
[TBL] [Abstract][Full Text] [Related]
48. Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka.
Rao RU; Samarasekera SD; Nagodavithana KC; Dassanayaka TDM; Punchihewa MW; Ranasinghe USB; Weil GJ
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006066. PubMed ID: 29084213
[TBL] [Abstract][Full Text] [Related]
49. Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study).
Lake SJ; Phelan SL; Engelman D; Sokana O; Nasi T; Boara D; Gorae C; Schuster T; Grobler AC; Osti MH; Andrews R; Marks M; Whitfeld MJ; Romani L; Kaldor J; Steer A
BMJ Open; 2020 Aug; 10(8):e037305. PubMed ID: 32868360
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
[TBL] [Abstract][Full Text] [Related]
51. Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications.
Kyelem D; Sanou S; Boatin B; Medlock J; Coulibaly S; Molyneux DH
Ann Trop Med Parasitol; 2003 Dec; 97(8):827-38. PubMed ID: 14754495
[TBL] [Abstract][Full Text] [Related]
52. Flubendazole as a macrofilaricide: History and background.
Geary TG; Mackenzie CD; Silber SA
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006436. PubMed ID: 30650160
[TBL] [Abstract][Full Text] [Related]
53. High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin.
Mmbando BP; Suykerbuyk P; Mnacho M; Kakorozya A; Matuja W; Hendy A; Greter H; Makunde WH; Colebunders R
Infect Dis Poverty; 2018 Jun; 7(1):64. PubMed ID: 29921319
[TBL] [Abstract][Full Text] [Related]
54. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
Ramaiah KD; Vanamail P; Pani SP; Yuvaraj J; Das PK
Trop Med Int Health; 2002 Sep; 7(9):767-74. PubMed ID: 12225508
[TBL] [Abstract][Full Text] [Related]
55. Twelve-month longitudinal parasitological assessment of lymphatic filariasis-positive individuals: impact of a biannual treatment with ivermectin and albendazole.
Kanamitie JN; Ahorlu CS; Otchere J; Aboagye-Antwi F; Kwansa-Bentum B; Boakye DA; Biritwum NK; Wilson MD; de Souza DK
Trop Med Int Health; 2017 Nov; 22(11):1451-1456. PubMed ID: 28891597
[TBL] [Abstract][Full Text] [Related]
56. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
[TBL] [Abstract][Full Text] [Related]
57. Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial.
Romani L; Marks M; Sokana O; Nasi T; Kamoriki B; Wand H; Whitfeld MJ; Engelman D; Solomon AW; Steer AC; Kaldor JM
Lancet Glob Health; 2018 Oct; 6(10):e1132-e1138. PubMed ID: 30223985
[TBL] [Abstract][Full Text] [Related]
58. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
[TBL] [Abstract][Full Text] [Related]
59. Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia.
Eneanya OA; Gankpala L; Goss CW; Bolay FK; Weil GJ; Fischer PU
Am J Trop Med Hyg; 2021 Nov; 106(2):700-709. PubMed ID: 34814104
[TBL] [Abstract][Full Text] [Related]
60. Profiling the best-performing community medicine distributors for mass drug administration: a comprehensive, data-driven analysis of treatment for schistosomiasis, lymphatic filariasis, and soil-transmitted helminths in Uganda.
Chami GF; Kabatereine NB; Tukahebwa EM
BMC Med; 2019 Mar; 17(1):69. PubMed ID: 30917824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
